The efficacy and safety of prophylactic antibiotics for post‐acute stroke infection: A systematic review and meta‐analysis

• Published in: British journal of clinical pharmacology 2023-03, Vol.89 (3), p.946-955
• Main Authors: Wang, Qing, Wu, Zi‐Yang, Tang, Hui‐Lin, Yi, Zhan‐Miao, Zhai, Suo‐Di
• Format: Article
• Language: English
• Subjects: acute stroke; Anti-Bacterial Agents - adverse effects; efficacy; Humans; Incidence; infection; Pneumonia - drug therapy; Pneumonia - epidemiology; Pneumonia - prevention & control; prophylactic antibiotics; safety; Stroke - complications; Stroke - drug therapy; Urinary Tract Infections - drug therapy; Urinary Tract Infections - etiology; Urinary Tract Infections - prevention & control
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1111/bcp.15646

Aims Infections are common complications after stroke and associated with unfavourable outcomes. We aimed to evaluate the efficacy and safety of prophylactic antibiotics for post‐acute stroke infection. Methods We searched PubMed, Embase, the Cochrane Library, SinoMed, China National Knowledge Infrastructure, WanFang Data, China Science and Technology Journal Database, and clinical trial register platforms from inception to 15 February 2022. We included randomized clinical trials that evaluated the efficacy and safety of prophylactic antibiotics. Primary outcomes were mortality rate and incidence of pneumonia. The pooled risk ratio (RR) and mean differences with 95% confidence interval (CI) were calculated using the random or fixed‐effect model depending on heterogeneity. The quality of evidence was evaluated using the Grading of Recommendations, Assessment, Development and Evaluations. Results Twelve studies (4809 participants) were included. There was no significant difference in the mortality rate (12 trials, n = 4740, RR 1.03 [95% Cl: 0.91–1.16], high‐quality evidence), incidence of pneumonia (7 trials, n = 4352, RR 0.94 [95% CI: 0.79–1.11], high‐quality evidence) and the incidence of adverse events between the prophylactic antibiotics and control groups. Prophylactic antibiotics significantly reduced the incidence of infections (8 trials, n = 4517, RR 0.72 [95% CI: 0.58–0.89], moderate‐quality evidence) and urinary tract infections (7 trials, n = 4352, RR 0.39 [95% CI: 0.3–0.49], moderate‐quality evidence). None of the subgroup analyses showed a significant difference in mortality or the incidence of pneumonia. Conclusion For acute stroke patients, prophylactic antibiotics were significantly associated with fewer incidences of any infections and urinary tract infections without significant differences in mortality rate and pneumonia.